6,678 trials
Healthy Subjects
Primary: Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s) — 29; 0; 29; 29 Number of Events
Onychomycosis · Dermatophytosis
Primary: Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO) — 19 Participants
Rheumatoid Arthritis
Primary: PDUS — 28.68; 19.52; 12.17 units on a scale — p=<0.0001
Post Operative Pain
Primary: Post Operative Morphine Consumption — 1; 0; 1; 1 mg — p=0.60
Acute Respiratory Distress
Primary: First Pass Success in Patients Undergoing Emergency Intubation, Intubated With Either Direct Larynogoscopy or Video Laryngoscopy Using a C-MAC Device. — 86.3; 92.2…
Type 2 Diabetes Mellitus
Primary: Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) — 5; 51 Participants
Type 2 Diabetes Mellitus
Primary: Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) — 7; 7; 57; 69 Participants
Shock
Primary: Patient Accrual Rate Over One Year (% of Target Sample Size Achieved) — 82 percentage of target sample size
Hip Dysplasia · Femoroacetabular Impingement · Acetabular Labrum Tear
Primary: Visual Analog Scale — 2.65; 2.50 units on a scale
Alzheimer Dementia (AD)
Primary: Adverse Events — 15; 16 Participants
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Plaque Psoriasis
Primary: Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16 — 7; 2 Participants
Amyloid Beta Protein
Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Tobacco Use Disorder · Homelessness
Primary: Number of Participants Self-reported and Bioverified Abstinent From Smoking — 13; 5 Participants